Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
02 2019
Historique:
received: 13 06 2018
revised: 23 07 2018
accepted: 26 07 2018
pubmed: 11 9 2018
medline: 19 11 2019
entrez: 11 9 2018
Statut: ppublish

Résumé

The survival impact of specific body composition changes during preoperative chemotherapy in patients with colorectal liver metastases undergoing curative-intent surgery remains unclear. This study aimed to determine the impact of changes in body weight and muscle mass during preoperative chemotherapy on survival after hepatectomy in patients with colorectal liver metastases. Consecutive patients with colorectal liver metastases undergoing preoperative chemotherapy and curative hepatectomy during 2009-2013 were retrospectively analyzed. Recurrence-free and overall survival were examined according to body compositions, including muscle mass, as measured by skeletal muscle index (area of muscle [cm The median follow-up duration in overall 169 patients was 47 months. Skeletal muscle index and body weight changed significantly during chemotherapy (skeletal muscle index: -0.52 cm Major loss of muscle mass but not body weight loss during preoperative chemotherapy is significantly associated with poor recurrence-free survival after hepatectomy in patients with colorectal liver metastases. The mechanisms mediating this association may inform future trials on maintaining muscle mass with dedicated nutrition and exercise programs to improve outcomes.

Sections du résumé

BACKGROUND
The survival impact of specific body composition changes during preoperative chemotherapy in patients with colorectal liver metastases undergoing curative-intent surgery remains unclear. This study aimed to determine the impact of changes in body weight and muscle mass during preoperative chemotherapy on survival after hepatectomy in patients with colorectal liver metastases.
METHODS
Consecutive patients with colorectal liver metastases undergoing preoperative chemotherapy and curative hepatectomy during 2009-2013 were retrospectively analyzed. Recurrence-free and overall survival were examined according to body compositions, including muscle mass, as measured by skeletal muscle index (area of muscle [cm
RESULTS
The median follow-up duration in overall 169 patients was 47 months. Skeletal muscle index and body weight changed significantly during chemotherapy (skeletal muscle index: -0.52 cm
CONCLUSION
Major loss of muscle mass but not body weight loss during preoperative chemotherapy is significantly associated with poor recurrence-free survival after hepatectomy in patients with colorectal liver metastases. The mechanisms mediating this association may inform future trials on maintaining muscle mass with dedicated nutrition and exercise programs to improve outcomes.

Identifiants

pubmed: 30197278
pii: S0039-6060(18)30488-4
doi: 10.1016/j.surg.2018.07.031
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

329-336

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Masayuki Okuno (M)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Claire Goumard (C)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Scott Kopetz (S)

Department of Gastrointestinal Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Eduardo A Vega (EA)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Katharina Joechle (K)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Takashi Mizuno (T)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Ching-Wei D Tzeng (CD)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Yun Shin Chun (YS)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Jeffrey E Lee (JE)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Jean-Nicolas Vauthey (JN)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Thomas A Aloia (TA)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX.

Claudius Conrad (C)

Department of Surgical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: claudius@cconrad.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH